The gerbil elevated plus-maze I: Behavioral characterization and pharmacological validation

Neuropsychopharmacology

Volumn 27, Issue 3, 2002, Pages 357-370

  Varty, Geoffrey B ^a   Morgan, Cynthia A ^a   Cohen Williams, Mary E ^a   Coffin, Vicki L ^a   Carey, Galen J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antidepressant drugs; Anxiety; Anxiolytic drugs; Benzodiazepines; Elevated plus maze; Fear; Gerbil

Indexed keywords

AMPHETAMINE; ANXIOLYTIC AGENT; BETA CARBOLINE; BUSPIRONE; CHLORDIAZEPOXIDE; DIAZEPAM; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; NEUROKININ 1 RECEPTOR; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOSTIMULANT AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; EXPLORATORY BEHAVIOR; FEMALE; GERBIL; LOCOMOTION; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RISK ASSESSMENT;

ADRENERGIC UPTAKE INHIBITORS; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CARBOLINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EVALUATION STUDIES; EXPLORATORY BEHAVIOR; FEMALE; GABA ANTAGONISTS; GERBILLINAE; HALOPERIDOL; MAZE LEARNING; MOTOR ACTIVITY; PSYCHOLOGICAL TESTS;

EID: 0036711461     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00312-3     Document Type: Article

References (63)

1. Arch J.R., Wilson S. Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes. Int J Obes Relat Metab Disord. 20:1996;191-199.
2. Ballard T.M., Sanger S., Higgins G.A. Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK(1) receptor antagonist. Eur J Pharmacol. 412:2001;255-264.
3. Beresford I.J., Birch P.J., Hagan R.M., Ireland S.J. Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345. Br J Pharmacol. 104:1991;292-293.
4. Blanchard R.J., Blanchard D.C., Weiss S.M., Meyer S. The effects of ethanol and diazepam on reactions to predatory odors. Pharmacol Biochem Behav. 35:1990;775-780.
5. Bristow L.J., Young L. Chromodacryorrhea and repetitive hind paw tapping. models of peripheral and central tachykinin NK1 receptor activation in gerbils Eur J Pharmacol. 253:1994;245-252.
6. Bruinvels A.T., Lery H., Nozulak J., Palacios J.M., Hoyer D. 5-HT1D binding sites in various species. similar pharmacological profile in dog, monkey, calf, guinea-pig and human brain membranes Naunyn Schmiedebergs Arch Pharmacol. 346:1992;243-248.
7. Cao B.J., Rodgers R.J. Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze. Neuropharmacology. 36:1997;1089-1097.
8. 1A agonist, 8-OH-DPAT in the social interaction test in gerbils. Brain Res. 915:2001;170-175.
9. Clark M.M., Galef B.G. Jr. Environmental influence on development, behavior, and endocrine morphology of gerbils. Physiol Behav. 27:1981;761-765.
10. Clark M.M., Galef B.G. Jr. Environmental effects on the ontogeny of exploratory and escape behaviors of Mongolian gerbils. Devel Psychobiol. 15:1982;121-129.
11. Cole B.J., Hillmann M., Seidelmann D., Klewer M., Jones G.H. Effects of benzodiazepine receptor partial inverse agonists in the elevated plus maze test of anxiety in the rat. Psychopharmacology (Berl). 121:1995;118-126.
12. Cole J.C., Rodgers R.J. Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test. comparison with haloperidol Psychopharmacology (Berl). 114:1994;288-296.
13. Collinson N., Dawson G.R. On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635. Psychopharmacology (Berl). 132:1997;35-43.
14. Creese I., Iverson S.D. Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Brain Res. 55:1973;369-382.
15. Cruz A.P., Frei F., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav. 49:1994;171-176.
16. Cutler M.G. Behavioral effects in gerbils of the 5-HT3 receptor antagonists, BRL 43694 and ICS 205-930, under circumstances of high and low light intensity. Neuropharmacology. 29:1990;515-520.
17. Cutler M.G., Piper D.C. Chronic administration of the 5-HT3 receptor antagonist BRL 43694; effects on reflex epilepsy and social behaviour of the Mongolian gerbil. Psychopharmacology (Berl). 101:1990;244-249.
18. Dalvi A., Rodgers R.J. Behavioral effects of diazepam in the murine plus-maze. flumazenil antagonism of enhanced head dipping but not the disinhibition of open-arm avoidance Pharmacol Biochem Behav. 62:1999;727-734.
19. Ellard C.G., Stewart D.J., Donaghy S., Vanderwolf C.H. Behavioral effects of neocortical and cingulate lesions in the Mongolian gerbil. Behav Brain Res. 36:1990;41-51.
20. Field K.J., Sibold A.L. The Laboratory Hamster & Gerbil (Ed. M. Suckow). 1999;CRC Press, Boca Raton, FL.
21. File S.E. NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats. Psychopharmacology (Berl). 152:2000;105-109.
22. File S.E., Cheeta S., Akanezi C. Diazepam and nicotine increase social interaction in gerbils. a test for anxiolytic action Brain Res. 888:2001;311-313.
23. Gitter B.D., Waters D.C., Bruns R.F., Mason N.R., Nixon J.A., Howbert J.J. Species differences in affinities of non-peptide antagonists for substance P receptors. Eur J Pharmacol. 197:1991;237-238.
24. Glick S.D. Changes in amphetamine sensitivity following frontal cortical damage in rats and mice. Eur J Pharmacol. 20:1972;351-356.
25. Graham E.A., Turpin M.P., Stubbs C.M. Characterisation of the tachykinin-induced hindlimb thumping response in gerbils. Neuropeptides. 4:1993;228.
26. Griebel G., Moreau G.-L., Jenck F., Martin J.R., Misslin R. Some critical determinants of the behaviour of rats in the elevated plus-maze. Behav Proc. 29:1993;37-48.
27. Griebel G., Rodgers R.J., Perrault G., Sanger D.J. Risk assessment behaviour. evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test Pharmacol Biochem Behav. 57:1997;817-827.
28. Hascoet M., Bourin M., Colombel M.C., Fiocco A.J., Baker G.B. Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol Biochem Behav. 65:2000;339-344.
29. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav. 54:1996;21-30.
30. Koks S., Beljajev S., Koovit I., Abramov U., Bourin M., Vasar E. 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology (Berl). 153:2001;365-372.
31. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt-Knowles E., Hale J.J., Mills S.G., MacCoss M., Swain C.J., Harrison T., Hill R.G., Hefti F., Scolnick E.M., Cascieri M.A., Chicchi G.G., Sadowski S., Williams A.R., Hewson L., Smith D., Rupniak N.M.J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1998;1640-1645.
32. Kurt M., Arik A.C., Celik S. The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice. J Basic Clin Physiol Pharmacol. 11:2000;173-180.
33. Lapin I.P. Anxiogenic effect of phenylethylamine and amphetamine in the elevated plus-maze in mice and its attenuation by ethanol. Pharmacol Biochem Behav. 44:1993;241-243.
34. Lee C.C., Rodgers R.R. Effects of buspirone on antinociceptive and behaviourial responses to the elevated plus-maze in mice. Behav Pharmacol. 2:1991;491-496.
35. Liggett S.B. Functional properties of the rat and human beta 3-adrenergic receptors. differential agonist activation of recombinant receptors in Chinese hamster ovary cells Mol Pharmacol. 42:1992;634-637.
36. Lightowler S., Kennett G.A., Williamson I.J., Blackburn T.P., Tulloch I.F. Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav. 49:1994;281-285.
37. Limberger N., Deicher R., Starke K. Species differences in presynaptic serotonin autoreceptors. mainly 5-HT1B but possibly in addition 5-HT1D in the rat, 5-HT1D in the rabbit and guinea-pig brain cortex Naunyn Schmiedebergs Arch Pharmacol. 343:1991;353-364.
38. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl). 92:1987;180-185.
39. Molewijk H.E., Hartog K., van der Poel A.M., Mos J., Olivier B. Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs. Psychopharmacology (Berl). 128:1996;31-38.
40. Molewijk H.E., van der Poel A.M., Mos J., van der Heyden J.A., Olivier B. Conditioned ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening anti-panic drugs. Psychopharmacology (Berl). 117:1995;32-40.
41. Moser P.C. An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone. Psychopharmacology (Berl). 99:1989;48-53.
42. Nikolaus S., Huston J.P., Hasenohrl R.U. The neurokinin-1 receptor antagonist WIN51,708 attenuates the anxiolytic-like effects of ventralpallidal substance P injection. Neuroreport. 10:1999;2293-2296.
43. Papp M., Vassout A., Gentsch C. The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav Brain Res. 115:2000;19-23.
44. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 14:1985;149-167.
45. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze. a novel test of anxiety in the rat Pharmacol Biochem Behav. 24:1986;525-529.
46. Podhorna J., Brown R.E. Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety. Br J Pharmacol. 130:2000;739-746.
47. Rodgers R.J. Animal models of 'anxiety'. where next? Behav Pharmacol. 8:1997;477-504.
48. Rodgers R.J., Cole J.C., Aboualfa K., Stephenson L.H. Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze. Pharmacol Biochem Behav. 52:1995;805-813.
49. Rodgers R.J., Johnson N.J. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav. 52:1995;297-303.
50. Routtenberg A., Kramis R.C. "Foot-stomping" in the gerbil. Rewarding brain stimulation, sexual behavior, and foot shock Nature. 214:1967;173-174.
51. Rupniak N.M., Williams A.R. Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK1 receptor antagonists. Eur J Pharmacol. 265:1994;179-183.
52. Rupniak N.M.J., Carlson E.C., Harrison T., Oates B., Seward E., Owen S., de Felipe C., Hunt S., Wheeldon A. Pharmacological blockade or genetic deletion of substance P (NK1) receptors attenuates neonatal vocalisation in guinea pigs and mice. Neuropharmacology. 39:2000;1413-1421.
53. Santarelli L., Gobbi G., Debs P.C., Sibille E.L., Blier P., Hen R., Heath M.J.S. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonin function. Proc Natl Acad Sci. 98:2001;1912-1917.
54. Saria A. The tachykinin NK1 receptor in the brain. pharmacology and putative functions Eur J Pharmacol. 375:1999;51-60.
55. Schatzberg A.F. New indications for antidepressants. J Clin Psychiatry. 61(Suppl 11):2000;9-17.
56. Schreiber R., Melon C., De Vry J. The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology (Berl). 135:1998;383-391.
57. Silva M.T., Alves C.R., Santarem E.M. Anxiogenic-like effect of acute and chronic fluoxetine on rats tested on the elevated plus-maze. Braz J Med Biol Res. 32:1999;333-339.
58. Silva R.C., Brandao M.L. Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze. an ethological analysis Pharmacol Biochem Behav. 65:2000;209-216.
59. Taylor K.M., Snyder S.H. Amphetamine. Differentiation by d- and l-isomers of behavior involving brain norepinephrine or dopamine Science. 168:1970;1487-1489.
60. Teixeira R.M., Santos A.R., Ribeiro S.J., Calixto J.B., Rae G.A., De Lima T.C. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol. 311:1996;7-14.
61. Varty GB, Morgan CA, Cohen-Williams M, Coffin VL (2000): Pharmacological validation of a novel gerbil elevated plus-maze: Effects of neurokinin NK1 receptor antagonists. Abstracts of the Society for Neuroscience 26:659.12
62. Vassout A., Veenstra S., Hauser K., Ofner S., Brugger F., Schilling W., Gentsch C. NKP608. a selective NK-1 receptor antagonist with anxiolytic-like effects in the social interaction and social exploration test in rats Regul Pept. 96:2000;7-16.
63. Zohar J., Westenberg H.G. Anxiety disorders. a review of tricyclic antidepressants and selective serotonin reuptake inhibitors Acta Psychiatr Scand (Suppl. 403):2000;39-49.